Commercialization: Page 73
-
PharmaVoice Team/PharmaVoice
Phase II: Testing Efficacy, Planning for Marketing
Pharmaceutical companies and their partners are working to address productivity and create efficiency in Phase II development. New types of trial designs, such as adaptive trials, are being considered as solutions to these perennial issues. “There are innovative ways in which biopharmaceutical co...
By Denise Myshko • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Phase I: Patient Recruitment
According to Peter Smith, Ph.D., senior VP, nonclinical development sciences at Millennium Pharmaceuticals: The Takeda Oncology Company, shortages in funding, manpower, and patient availability have created the proverbial perfect storm in the current clinical trial system. “The fact that traditio...
By Denise Myshko • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharmaceutical POOL John DUCKER, APP Pharmaceuticals Dr. Julie GERBERDING, Merck Dr. Michael ROSENBLATT, Merck Sean NOLAN, Lundbeck Inc. Derica RICE, Lilly Biotechnology POOL Dr. Mark BAGARAZZI, Inovio Biomedical Hans BISHOP, Dendreon Suzanne CADDEN, ImmunoGen Dr. Thomas HOFSTAETTER, VaxInnate Dr...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
E-media
New Electronic and Web-based Applications, Sites, and Technologies Featured Briefs: Perceptive Informatics Introduces E-Clinical Suite Elsevier Launches Online Resource Center for ARRA Updates Thomson Pharma Database Integrates Trial Protocol, Outcome Info Take Supply Chain Releases Multi-Tenant ...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
What's New
New Healthcare-related Products, Services, and Companies Featured Briefs: GxP Consulting Adds Statistical Analysis Support Former Wyeth VP Launches Petkus Communications Consultants GlobalHealth Provides Corporate Training, Degree Programs Newly Formed Durata Therapeutics Acquires Pfizer’s Vicuro...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: Process Inefficiencies Cause $11 Billion in Annual Pharma Revenue Leakage Sidebar: Key Findings of Revenue Leakage Study Drug Companies Still Under Pressure to Increase Pace of Development Sidebar: Key Near-Term Trends i...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Upfront
According to industry experts, the impact of the updated REMS policy in 2007 has had limited impact on the industry thus far. The FDA was granted expanded authority to require REMS (risk evaluation and mitigation strategies) for new drug applications or for existing drugs where the FDA has determ...
By PharmaVoice Team • March 4, 2010 -
PharmaVoice Team/PharmaVoice
Opportunities in Oncology Development
Advances in cancer research, knowledge, treatment options, and awareness have increased tremendously in the past 25 years. Rates of new diagnoses and deaths from all cancers have declined significantly for men and women overall and for most racial and ethnic populations in the United States, acco...
By PharmaVoice Team • Jan. 28, 2010 -
PharmaVoice Team/PharmaVoice
Help Wanted: Pharma Bloggers
Social media specialist positions are growing exponentially — just Google the term to view the jobs that pop up. Many colleges and universities are now offering degrees in how to write, publish, and strategize in this new media field. Hospitals, clinics, and other healthcare organizations have en...
By Robin Robinson • Jan. 26, 2010 -
PharmaVoice Team/PharmaVoice
A 360-Degree View of E-Patient Connections
Healthcare information technology has created the platform for the exchange, collection, and documentation of health data and information, but it is up to the crucial players — patients, physicians, pharma companies, and service providers — to make e-connections work. The patient, the physician, ...
By PharmaVoice Team • Jan. 26, 2010 -
PharmaVoice Team/PharmaVoice
Talent Pool
Biotechnology POOL Dr. Paul LAMMERS Mirna Appoints Chief Executive Mirna Therapeutics has named Paul Lammers, M.D., president and CEO. As head of Mirna, Dr. Lammers is responsible for driving the company’s discoveries in the field of microRNA (miRNA) into the clinic. Dr. Lammers was previously pr...
By PharmaVoice Team • Jan. 26, 2010 -
PharmaVoice Team/PharmaVoice
E-media
New Electronic and Web-based Applications, Sites, and Technologies Featured Briefs: IntraLinks, Adobe Collaborate on Data-Capture Solutions for Clinical Trials Maestro eLearning Creates e-Learning Library Deloitte Recap Helps Biopharma Executives Make Portfolio Decisions Thomson Reuters Unveil...
By PharmaVoice Team • Jan. 26, 2010 -
PharmaVoice Team/PharmaVoice
What's New
New Healthcare-related Products, Services, and Companies Featured Briefs: Pharma Industry Veteran Launches Online Recruitment Site FlightPath Enables Interactive Commercialization Planning Expanded SDI Media Services Measure Pharma Ad Campaign ROI New Team Aligns Parexel Experts With Biopharm...
By PharmaVoice Team • Jan. 25, 2010 -
PharmaVoice Team/PharmaVoice
PharmaTrax
Sales, Marketing, and R&D Trends from Industry Analysts Featured Briefs: Companies Advised to Communicate with Payers Earlier in Drug Development Sidebar: Average Allocation of a Managed Markets Department’s Personnel Pharma Companies Add Employer Market to the Mix Sidebar: Employer Programs...
By PharmaVoice Team • Jan. 25, 2010 -
PharmaVoice Team/PharmaVoice
Upfront
Honors and Awards G&A Receives Recognition The Rx Club presented Goble & Associates (G&A) with nine Awards of Excellence for a variety of ad campaigns, sales aids, launch campaigns, patient education brochures, and Web sites. In addition, G&A received two Gold and five Silver Awa...
By PharmaVoice Team • Jan. 25, 2010 -
PharmaVoice Team/PharmaVoice
Brand Champions
The role of the is being played by branding companies, advertising agencies,by the companies that are in charge of producing materials and giving strategic advice to pharmaceutical companies.There are few companies that have a brand champion. Vince Parry TOO OFTEN BRANDING IS MISTAKEN FOR AN ADVE...
By PharmaVoice Team • Jan. 18, 2010 -
PharmaVoice Team/PharmaVoice
No Pain, Big Gain
Daily injections are a painful way of life for an estimated 3.7 mil lion Americans who are insulin dependent diabetics. The condi tion, characterized by high blood sugar levels that result from defects in the body’s ability to produce and/or use insulin, is the fifth leading cause of death by dis...
By PharmaVoice Team • Jan. 18, 2010 -
PharmaVoice Team/PharmaVoice
The Patient Pipeline
CLINICAL TRIAL RECRUITMENT AND ENROLLMENT EFFORTS ARE OFTEN NOT GIVEN HIGH PRIORITY, causing costly delays in the develop ment of new drugs. Unfortunately, there are no quick fixes, but companies are beginning to institute wellthought out and designed processes to bring the right patients to the ...
By PharmaVoice Team • Jan. 18, 2010 -
PharmaVoice Team/PharmaVoice
Talent Pool
Pharma POOL Mark BOOTH Takeda Pharmaceuticals North America Names President Takeda Pharmaceuticals North America Inc. (TPNA), a wholly owned subsidiary of Takeda Chemical Industries Ltd., has restructured its senior executive team and named Mark Booth president. Mr. Booth, an 18year veteran of th...
By PharmaVoice Team • Jan. 14, 2010 -
PharmaVoice Team/PharmaVoice
PharmaTrax
SALES, MARKETING, AND R&D TRENDS AFFECTING THE HEALTHCARE INDUSTRY NestEggz Survey Suggests PATIENTS WHO SAVE ON PRESCRIPTIONS TAKE THEIR MEDICATION Almost 90% of cholesterol patients enrolled in NestEggz were found to take their medication daily, almost double the national average.NestEggz,a...
By PharmaVoice Team • Jan. 14, 2010 -
PharmaVoice Team/PharmaVoice
For Art's Sake
Catchy, creative, and memorable are three words to describe this month’s selection of standout creative executions. Two of the ad campaigns, Viagra and Glucotrol XL, were executed by Cline, Davis &Mann on behalf of client Pfizer Inc. The first of the ads was cre ated for the launch of Viagra....
By PharmaVoice Team • Jan. 14, 2010 -
PharmaVoice Team/PharmaVoice
Pharma Outlet
For the first time since the Food and Drug Administration lessened restrictions on direct to consumer pharmaceutical advertisements in 1996, there is a significant slowing in direct to consumer advertising expenditures. From 1996 to 2000, directtoconsumer advertising spending grew more than three...
By Susan Hempstead • Jan. 14, 2010 -
PharmaVoice Team/PharmaVoice
What's on Your Mind: Opinions
The economy In my opinion, the biggest impact on the industry has been the fallout from the economic downturn. A climate of near paralysis has seized much of the industry and I don’t expect that climate to change much until well into 2003. The uncertainty of the timing of the eco nomic turnaround...
By PharmaVoice Team • Jan. 14, 2010 -
PharmaVoice Team/PharmaVoice
Raise your voice: Letters
Turn up the volume Each month, our team looks forward to what’s inside the next issue of PharmaVoice. It’s fresh, uncanny in its timeliness, and always relevant. (Like us.) Evenhanded panels of industry experts help us weigh the issues that are going to matter, and the statistics are so fresh tha...
By PharmaVoice Team • Jan. 14, 2010 -
PharmaVoice Team/PharmaVoice
Letter from the Editor
PharmaVOICE A product lives on a shelf. A brand lives in the mind of the consumer . The challenge, according to industry experts, is making an emotional connection between the two. A brand goes beyond the rational; a brand is the promise the product offers the customer or stakeholder, whether tha...
By PharmaVoice Team • Jan. 14, 2010
Previous
